Tolerability of Tapinarof for AD Management

EP: 1.Current Landscape of Atopic Dermatitis (AD)

EP: 2.The Mechanisms of Action of AD Treatments

EP: 3.Reviewing New Tapinarof Data for Atopic Dermatitis Treatment

EP: 4.Use of Nonsteroidal Formulations in AD Treatment

EP: 5.Clinical Trial Data for Use of Tapinarof in AD

EP: 6.Patient Baseline Characteristics in AD Tapinarof Clinical Trials

EP: 7.Rapid Itch Reduction Data With Tapinarof in AD

EP: 8.vIGA-AD Response Data With Tapinarof

EP: 9.EASI75 Response for Tapinarof in AD

Now Viewing

EP: 10.Tolerability of Tapinarof for AD Management

EP: 11.Final Thoughts on Tapinarof in AD Clinical Trials

This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD.

The speaker addresses the crucial aspect of tolerability and safety in relation to tapinarof during clinical trials for atopic dermatitis. Emphasizing the significance of patient concerns about tolerability and safety, the speaker discusses the low incidence of treatment-related adverse events. Discontinuation rates for tapinarof were notably lower than the vehicle, ranging from 1.5% to 2%, suggesting a favorable safety profile and patient adherence to the therapy.

The discussion delves into three treatment-emergent adverse events of special interest: contact dermatitis, follicular events, and headaches. Despite the approval of tapinarof for psoriasis in patients aged 18 years and above, the speaker notes the careful consideration of previous psoriasis trial data when designing the atopic dermatitis trials. Contact dermatitis, at 1.5%, was surprisingly higher in the vehicle group. Follicular events, associated with psoriasis trials, were more prevalent in the tapinarof group, but the speaker underscores the manageable nature of mild folliculitis. Headaches, a common clinical trial occurrence, were more frequent in the tapinarof group without a clear explanation.

The speaker acknowledges the transparency in presenting the data, emphasizing the absence of an attempt to hide any information. Despite the challenges posed by follicular events and headaches, the overall low discontinuation rates indicate that these events did not significantly impact participants' ability to continue the therapy. The discussion concludes with a recognition of the need for further investigation into these adverse events, particularly the follicular events, and an emphasis on understanding patient profiles to glean more insights.

Video synopsis is AI-generated and reviewed by Dermatology Times editorial staff.